[go: up one dir, main page]

AR081400A1 - Una composicion farmaceutica de liberacion controlada de losartan - Google Patents

Una composicion farmaceutica de liberacion controlada de losartan

Info

Publication number
AR081400A1
AR081400A1 ARP110101685A ARP110101685A AR081400A1 AR 081400 A1 AR081400 A1 AR 081400A1 AR P110101685 A ARP110101685 A AR P110101685A AR P110101685 A ARP110101685 A AR P110101685A AR 081400 A1 AR081400 A1 AR 081400A1
Authority
AR
Argentina
Prior art keywords
losartan
pharmaceutical composition
controlled liberation
controlled release
controlled
Prior art date
Application number
ARP110101685A
Other languages
English (en)
Inventor
Guerra Antonio Sereno
Blas David Loeches
Fernandez Varas
Roberto Molina
Cura Medina Estibaliz Del
Martinez Jose Miguel Rizo
Original Assignee
Liconsa Laboratorios Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liconsa Laboratorios Sa filed Critical Liconsa Laboratorios Sa
Publication of AR081400A1 publication Critical patent/AR081400A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composicion farmacéutica de liberacion controlada de losartan que comprende un nucleo de retencion gástrica con losartan y una cantidad comprendida entre 5 y 25% en peso de hidroxipropilmetilcelulosa como unico polímero de liberacion controlada, y una capa activa de liberacion inmediata que contiene Iosartan, a su procedimiento de preparacion y a su uso para la profilaxis y el tratamiento de la hipertension.
ARP110101685A 2010-05-21 2011-05-17 Una composicion farmaceutica de liberacion controlada de losartan AR081400A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382135A EP2392318A1 (en) 2010-05-21 2010-05-21 A pharmaceutical controlled release composition of losartan

Publications (1)

Publication Number Publication Date
AR081400A1 true AR081400A1 (es) 2012-08-29

Family

ID=42635468

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101685A AR081400A1 (es) 2010-05-21 2011-05-17 Una composicion farmaceutica de liberacion controlada de losartan

Country Status (7)

Country Link
EP (2) EP2392318A1 (es)
AR (1) AR081400A1 (es)
BR (1) BR112012029565A2 (es)
MX (1) MX2012013362A (es)
TW (1) TW201201800A (es)
UY (1) UY33393A (es)
WO (1) WO2011144724A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018002673A1 (en) * 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN119112811A (zh) * 2016-08-29 2024-12-13 北京科信聚润医药科技有限公司 一种氢氯噻嗪微片及其制备方法
IT201800011123A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione cronotropica di sartani

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438027A1 (en) 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
EP2086519B1 (en) * 2006-10-30 2017-06-21 HanAll Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors

Also Published As

Publication number Publication date
WO2011144724A1 (en) 2011-11-24
TW201201800A (en) 2012-01-16
MX2012013362A (es) 2013-05-01
BR112012029565A2 (pt) 2016-12-13
EP2571495A1 (en) 2013-03-27
UY33393A (es) 2011-12-30
EP2392318A1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CL2012002880A1 (es) Compuestos derivados de pirrolobenzodiazepinas conjugados, entre otros con anticuerpos; procedimiento de preparación de un conjugado; composicion farmaceutica: procedimiento de tratamiento de cancer; y su uso para proporcionar el compuesto a una localizacion diana que es una poblacion celular proliferativa; articulo de fabricacion
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
CR20120317A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
SV2011003853A (es) Compuestos organicos
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
ECSP12011703A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
ECSP099620A (es) Derivados de ciclohexano espirociclico
CL2011001860A1 (es) Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer.
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
AR081400A1 (es) Una composicion farmaceutica de liberacion controlada de losartan
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
CL2012002543A1 (es) Composicion endoparasiticida que comprende una combinacion de un compuesto de formula (i) derivado de amidoacetonitrilo y abamectina; y su uso para el control de endoparasitos, en particular helmintos.
CL2011001207A1 (es) Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos.
CO6592046A2 (es) 5-alquinil pirimidas y su uso como inhibidores de quinasa
DOP2011000374A (es) 17b-alquil-17a-oxi-estratrienos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure